|Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial; Positive Trial Data for Novartis' COPD Therapy.|
|By Staff and Wire Reports|
|Friday, 30 September 2011 18:29|
Pfizer Inc. (NYSE:PFE) reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND(R) (voriconazole) and ERAXIS(TM) (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.
The primary analysis of this double-blinded prospective randomized clinical trial was to compare mortality rates at six weeks after initiation of study treatment in patients with a diagnosis of proven or probable IA.
In the primary analysis, treatment with the combination of VFEND and ERAXIS resulted in a lower all-cause mortality rate at six weeks compared to VFEND alone. However, this difference in mortality did not achieve the pre-specified threshold for statistical superiority. The safety and tolerability of the combination of VFEND and ERAXIS in this study was similar to that of VFEND monotherapy.
Pfizer Inc. dropped -0.56% to $17.88 with the total traded volume of 9.83 million shares less than average volume of 48.53 million. Its 52 weeks price change was 4.72%. Its market capitalization is $139.58 billion.
Novartis AG (NYSE:NVS) has published positive data from new phase III clinical trials of its developmental chronic obstructive pulmonary disease (COPD) drug NVA237.
Results from the Glow1 and Glow3 studies have shown that the once-daily glycopyrronium bromide-based therapy can provide superior 24-hour bronchodilation and increased exercise endurance among COPD patients, compared to placebo.
Novartis will use the data to support its efforts to seek European regulatory approval for NVA237, which is to be marketed under the brand name Seebri Breezhaler.
Earlier this week, the company also announced data from a phase III study of Afinitor, showing its efficacy as a breast cancer therapy.
Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit (ALS Summit) on Saturday, October 1, 2011.
Array BioPharma Inc. (NASDAQ: ARRY) today announced results from a randomized Phase 2 placebo-controlled study conducted by AstraZeneca comparing the efficacy of selumetinib (AZD6244/ARRY-886) in combination with docetaxel with docetaxel alone in the second-line treatment of 87 patients prospectively selected with KRAS-mutant, locally advanced or metastatic non-small cell lung cancer.
Bristol-Myers Squibb Company (NYSE: BMY) announced today that 22 abstracts on the Company’s research in liver disease have been accepted for presentation at The Liver Meeting® 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD), in San Francisco, November 4 - 8.
EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that Gregory S. Lea, Senior Vice President and Chief Financial Officer, is scheduled to present at the Craig-Hallum 2nd Annual Alpha Select Conference in New York, NY on Thursday, October 6, 2011 at 8:40 am ET.
Esterline Corporation (NYSE: ESL), a leading specialty manufacturer serving the aerospace and defense markets, today announced that it has selected Phil Bowker to serve as Platform President of the company's Engineered Materials business platform, consisting of six global manufacturing operations in Mexico, the United Kingdom, and the U.S.
Healthnostics, Inc. (PINKSHEETS: HNSS) announced results for the 2nd Quarter ending June 30, 2011 of $298,518 in earnings on revenue of $403,220 as compared to the same period in 2010 of a $23,772 loss on revenue of $207,942.
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the appointments of Michael Grey and Ronald Pauli to the Company's Board of Directors.
Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that the Company continues efforts to reestablish DTC services.
Life Technologies Corporation (NASDAQ: LIFE) today announced open access to protocols detailing key steps of the Ion PGM™ sequencer workflow. Methods delivering the scalability, simplicity and speed that are at the core of Ion semiconductor sequencing are now openly posted on the Ion Community.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2011 sales and earnings conference call with institutional investors and analysts at 8 a.m. EDT on Friday, Oct. 28.
Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.
Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial (SB-509-901) from its ZFP Therapeutic® program to develop SB-509 as a treatment for diabetic neuropathy.
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold, in collaboration with Sarcoma Alliance for Research through Collaboration (SARC), have initiated a Phase 3 randomized clinical trial of TH-302 in patients with soft tissue sarcoma.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK™ (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting®, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS™ (boceprevir), the company’s first-in-class, oral hepatitis C virus (HCV) NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that Cuong Viet Do is stepping down from WuXi's board of directors effective immediately.